OTO-413

Otonomy, Inc. · Phase 1 active Small molecule

At a glance

Generic name	OTO-413
Sponsor	Otonomy, Inc.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

OTO-413 in Subjects With Speech-in-Noise Hearing Impairment (PHASE1, PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

OTO-413 CI brief — competitive landscape report
OTO-413 updates RSS · CI watch RSS
Otonomy, Inc. portfolio CI